OncoMatch/Clinical Trials/NCT05180097
Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma
Is NCT05180097 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for hodgkin lymphoma.
Treatment: Gemcitabine · Dexamethasone · Cisplatin · Brentuximab vedotin · Pembrolizumab — This study is being done to determine if two new drugs can shrink or eliminate classical Hodgkins lymphoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hodgkin Lymphoma
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: anthracycline-containing chemotherapy
relapsed or refractory disease after anthracycline-containing chemotherapy
Cannot have received: salvage systemic therapy
Participants who have received prior salvage systemic therapy for their relapsed or refractory disease.
Lab requirements
Blood counts
absolute neutrophils ≥1.0 x 10^9/l; platelets ≥75 x 10^9/l; hemoglobin ≥80 g/l
Kidney function
serum creatinine <1.55 x unl or creatinine clearance ≥30 ml/min
Liver function
bilirubin ≤1.50 x unl; ast and alt ≤2.50 x unl
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify